AIM: To identify survival prognostic factorsin patients who underwent curative pelvic exenteration from rectal adenocarcinoma(T4 tumors and isolated pelvic recurrence).
METHODS: Complete follow-up data were available on 27 patients who underwentthis surgical procedure between 1996 and 2006. Multiple prognostic factors werestudied by multivariate analysis (epidemiological, surgical and histological).
RESULTS: Postoperative mortality was 7 % (n=2) while overall morbiditywas 55 % (n=15). Mean of overall survival was 38 months. T4 tumors presentedmore long-time survival than pelvic recurrence (47 X 26 months). Lymph nodedisease (N+) was single adverse prognostic factor at multivariate analysis.
CONCLUSION: Pelvic exenteration presents both high morbidity and considerablemortality. It should be reserved for T4 tumors, principally when there was nolymph node spreading.
